Rafferty Asset Management, LLC - BRIDGEBIO PHARMA INC ownership

BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 225 filers reported holding BRIDGEBIO PHARMA INC in Q3 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.6%.

Quarter-by-quarter ownership
Rafferty Asset Management, LLC ownership history of BRIDGEBIO PHARMA INC
ValueSharesWeighting
Q3 2023$8,263,883
-7.5%
313,382
-39.6%
0.05%
-2.0%
Q2 2023$8,931,031
+57.8%
519,246
+52.1%
0.05%
+31.6%
Q1 2023$5,658,422
+3.2%
341,280
-52.6%
0.04%
-17.4%
Q4 2022$5,480,830
-6.7%
719,269
+21.8%
0.05%
-25.8%
Q3 2022$5,872,000
+42.7%
590,740
+30.4%
0.06%
+63.2%
Q2 2022$4,114,000
-35.0%
453,080
-27.3%
0.04%
+2.7%
Q1 2022$6,326,000
+160.3%
623,202
+327.7%
0.04%
+184.6%
Q4 2021$2,430,000
-16.2%
145,704
+135.5%
0.01%
-35.0%
Q3 2021$2,900,000
+16.6%
61,881
+51.7%
0.02%
+25.0%
Q2 2021$2,487,000
-14.0%
40,803
-13.1%
0.02%
-20.0%
Q1 2021$2,892,000
+167.5%
46,950
+209.0%
0.02%
+81.8%
Q4 2020$1,081,000
-34.9%
15,196
-65.7%
0.01%
-45.0%
Q3 2020$1,660,000
+52.9%
44,255
+32.9%
0.02%
+33.3%
Q2 2020$1,086,000
+60.9%
33,309
+73.1%
0.02%
+50.0%
Q4 2019$675,00019,2480.01%
Other shareholders
BRIDGEBIO PHARMA INC shareholders Q3 2023
NameSharesValueWeighting ↓
Aisling Capital Management LP 6,068,125$160,016,45665.94%
Kohlberg Kravis Roberts & Co. L.P. 31,060,971$819,077,80528.79%
Cormorant Asset Management, LP 4,662,530$122,950,9167.17%
Frazier Life Sciences Management, L.P. 2,725,949$71,883,2754.77%
Octagon Capital Advisors LP 971,639$25,622,1203.94%
M28 Capital Management LP 121,200$3,196,0443.66%
VIKING GLOBAL INVESTORS LP 25,120,991$662,440,5332.69%
BOONE CAPITAL MANAGEMENT LLC 313,381$8,263,8572.61%
Fernwood Investment Management, LLC 235,620$6,213,2992.23%
SOUTHPORT MANAGEMENT, L.L.C. 15,000$395,5502.15%
View complete list of BRIDGEBIO PHARMA INC shareholders